Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antibiotics, Antitubercular"" wg kryterium: Temat


Tytuł :
The antibiotic sorangicin A inhibits promoter DNA unwinding in a Mycobacterium tuberculosis rifampicin-resistant RNA polymerase.
Autorzy :
Lilic M; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Chen J; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Boyaci H; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Braffman N; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Hubin EA; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Herrmann J; Department Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarland University, 66123 Saarbrücken, Germany.; Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany.; Partner Site Hannover-Braunschweig, German Center for Infection Research, 38124 Braunschweig, Germany.
Müller R; Department Microbial Natural Products, Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research, Saarland University, 66123 Saarbrücken, Germany.; Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany.; Partner Site Hannover-Braunschweig, German Center for Infection Research, 38124 Braunschweig, Germany.
Mooney R; Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706.
Landick R; Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706.; Department of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706.
Darst SA; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065.
Campbell EA; Laboratory of Molecular Biophysics, The Rockefeller University, New York, NY 10065; .
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Dec 01; Vol. 117 (48), pp. 30423-30432. Date of Electronic Publication: 2020 Nov 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Promoter Regions, Genetic*
Aminoglycosides/*pharmacology
Antibiotics, Antitubercular/*pharmacology
DNA-Directed RNA Polymerases/*metabolism
Drug Resistance, Bacterial/*drug effects
Mycobacterium tuberculosis/*drug effects
Mycobacterium tuberculosis/*physiology
Aminoglycosides/chemistry ; Antibiotics, Antitubercular/chemistry ; Binding Sites ; Humans ; Models, Molecular ; Molecular Conformation ; Protein Binding ; Rifampin/pharmacology ; Structure-Activity Relationship ; Tuberculosis/drug therapy ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł :
Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
Autorzy :
Kouanda S; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso. .
Ouedraogo HG; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso.
Cisse K; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso.
Compaoré TR; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso.
Sulis G; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada.; McGill International TB Centre, McGill University, Montreal, QC, Canada.
Diagbouga S; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso.
Roggi A; Institute of Infectious and Tropical Diseases, Brescia University Hospital, Brescia, Italy.
Tarnagda G; Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Ouagadougou, 03BP7192, Burkina Faso.
Villani P; Institute of Pharmacology, IRCCS, San Matteo University Hospital, Pavia, Italy.
Sangare L; Yalgado Ouedraogo University Teaching Hospital, Ouagadougou, Burkina Faso.
Simporé J; Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
Regazzi M; Institute of Pharmacology, IRCCS, San Matteo University Hospital, Pavia, Italy.
Matteelli A; Institute of Infectious and Tropical Diseases, Brescia University Hospital, Brescia, Italy.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Jun 26; Vol. 20 (1), pp. 449. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji :
Journal Article
MeSH Terms :
AIDS-Related Opportunistic Infections/*drug therapy
Antibiotics, Antitubercular/*administration & dosage
Antibiotics, Antitubercular/*therapeutic use
Coinfection/*drug therapy
HIV Protease Inhibitors/*therapeutic use
Lopinavir/*therapeutic use
Rifabutin/*administration & dosage
Rifabutin/*therapeutic use
Ritonavir/*therapeutic use
Tuberculosis/*drug therapy
Adult ; Antibiotics, Antitubercular/adverse effects ; Antibiotics, Antitubercular/blood ; Burkina Faso ; Chromatography, High Pressure Liquid ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Microbial Sensitivity Tests ; Pilot Projects ; Random Allocation ; Rifabutin/adverse effects ; Rifabutin/blood ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?
Autorzy :
Fonseca AAD; Universidade Federal do Pará, Faculdade de Farmácia, Belém, PA, Brazil.
Pinto ACG; Universidade Federal do Pará, Faculdade de Farmácia, Belém, PA, Brazil.
Paixão TPD; Universidade Federal do Pará, Faculdade de Farmácia, Belém, PA, Brazil.
Albério CAA; Universidade Federal do Pará, Faculdade de Farmácia, Belém, PA, Brazil.
Vieira JLF; Universidade Federal do Pará, Faculdade de Farmácia, Belém, PA, Brazil. Electronic address: .
Pokaż więcej
Źródło :
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [Braz J Infect Dis] 2020 Jul - Aug; Vol. 24 (4), pp. 352-355. Date of Electronic Publication: 2020 Jun 11.
Typ publikacji :
Journal Article
MeSH Terms :
Antibiotics, Antitubercular/*blood
Diabetes Mellitus/*blood
Rifampin/*blood
Tuberculosis/*blood
Antibiotics, Antitubercular/therapeutic use ; Blood Glucose ; Chromatography, High Pressure Liquid ; Humans ; Male ; Rifampin/therapeutic use ; Tuberculosis/drug therapy
Czasopismo naukowe
Tytuł :
Factors associated with catastrophic total costs due to tuberculosis under a designated hospital service model: a cross-sectional study in China.
Autorzy :
Yang T; Institute of Tuberculosis Prevention and Control, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, Zhejiang, China. .
Chen T; Institute of Tuberculosis Prevention and Control, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, Zhejiang, China.
Che Y; Institute of Tuberculosis Prevention and Control, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, Zhejiang, China.
Chen Q; Division of Medical Insurance, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Bo D; Institute of Infectious Disease Control, Haishu District Center for Disease Control and Prevention, Ningbo, Zhejiang, China.
Pokaż więcej
Źródło :
BMC public health [BMC Public Health] 2020 Jun 26; Vol. 20 (1), pp. 1009. Date of Electronic Publication: 2020 Jun 26.
Typ publikacji :
Journal Article
MeSH Terms :
Cost of Illness*
Antibiotics, Antitubercular/*economics
Catastrophic Illness/*economics
Tuberculosis/*economics
Tuberculosis/*therapy
Adult ; Aged ; Antibiotics, Antitubercular/therapeutic use ; Catastrophic Illness/therapy ; China/epidemiology ; Cross-Sectional Studies ; Family Characteristics ; Female ; Health Care Costs ; Hospitalization/economics ; Humans ; Incidence ; Income/statistics & numerical data ; Male ; Middle Aged ; Rifampin/economics ; Socioeconomic Factors ; Tuberculosis/epidemiology
Czasopismo naukowe
Tytuł :
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial.
Autorzy :
Smits JAJ; Institute for Mental Health Research, Department of Psychology, The University of Texas at Austin, Austin.
Pollack MH; Department of Psychiatry, Rush University Medical Center, Chicago, Illinois.; Now with Myriad Genetics, Salt Lake City, Utah.
Rosenfield D; Department of Psychology, Southern Methodist University, Dallas, Texas.
Otto MW; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Dowd S; Department of Psychiatry, Rush University Medical Center, Chicago, Illinois.
Carpenter J; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Dutcher CD; Institute for Mental Health Research, Department of Psychology, The University of Texas at Austin, Austin.
Lewis EM; Department of Psychiatry, Rush University Medical Center, Chicago, Illinois.; Department of Psychology, Louisiana State University, Baton Rouge.
Witcraft SM; Institute for Mental Health Research, Department of Psychology, The University of Texas at Austin, Austin.; Department of Psychology, University of Mississippi, Oxford.
Papini S; Institute for Mental Health Research, Department of Psychology, The University of Texas at Austin, Austin.
Curtiss J; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Andrews L; Department of Psychology, Southern Methodist University, Dallas, Texas.; Department of Psychological and Brain Sciences, University of Delaware, Newark.
Kind S; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.; Department of Psychology, Suffolk University, Boston, Massachusetts.
Conroy K; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.; Department of Psychology, Florida International University, Coral Gables.
Hofmann SG; Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2020 Jun 01; Vol. 3 (6), pp. e206777. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :
Antibiotics, Antitubercular/*administration & dosage
Cycloserine/*administration & dosage
Implosive Therapy/*methods
Phobia, Social/*drug therapy
Adult ; Antibiotics, Antitubercular/therapeutic use ; Case-Control Studies ; Cycloserine/therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Male ; Phobia, Social/psychology ; Phobia, Social/therapy ; Placebos/administration & dosage ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
D-Cycloserine destruction by alanine racemase and the limit of irreversible inhibition.
Autorzy :
de Chiara C; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK.
Homšak M; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK.; Department of Chemistry, Imperial College London, The Molecular Sciences Research Hub, London, UK.
Prosser GA; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK.; Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.
Douglas HL; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK.
Garza-Garcia A; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK.
Kelly G; MRC Biomedical NMR Centre, The Francis Crick Institute, London, UK.
Purkiss AG; Structural Biology Science Technology Platform, The Francis Crick Institute, London, UK.
Tate EW; Department of Chemistry, Imperial College London, The Molecular Sciences Research Hub, London, UK.; Chemical Biology Satellite Laboratory, The Francis Crick Institute, London, UK.
de Carvalho LPS; Mycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, UK. .
Pokaż więcej
Źródło :
Nature chemical biology [Nat Chem Biol] 2020 Jun; Vol. 16 (6), pp. 686-694. Date of Electronic Publication: 2020 Mar 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Alanine Racemase/*metabolism
Antibiotics, Antitubercular/*chemistry
Cycloserine/*chemistry
Recombinant Proteins/*metabolism
Alanine/chemistry ; Alanine/metabolism ; Alanine Racemase/genetics ; Amino Acid Sequence ; Antibiotics, Antitubercular/metabolism ; Bacterial Proteins/metabolism ; Binding Sites ; Cycloserine/metabolism ; Escherichia coli ; Isoxazoles/chemistry ; Ligases/metabolism ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/enzymology ; Oximes/chemistry ; Protein Binding ; Protein Conformation ; Recombinant Proteins/genetics
Czasopismo naukowe
Tytuł :
Targeted protein degradation in antibacterial drug discovery?
Autorzy :
Gopal P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Dick T; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA; Department of Medical Sciences, Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, USA. Electronic address: .
Pokaż więcej
Źródło :
Progress in biophysics and molecular biology [Prog Biophys Mol Biol] 2020 May; Vol. 152, pp. 10-14. Date of Electronic Publication: 2019 Nov 16.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Antibiotics, Antitubercular/*chemistry
Bacterial Proteins/*metabolism
Proteolysis/*drug effects
Pyrazinamide/*chemistry
Tuberculosis/*drug therapy
Antibiotics, Antitubercular/pharmacology ; Drug Discovery ; Drug Resistance, Bacterial ; Humans ; Hydrophobic and Hydrophilic Interactions ; Molecular Targeted Therapy ; Protein Binding ; Pyrazinamide/pharmacology
Czasopismo naukowe
Tytuł :
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Autorzy :
Nabisere R; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Musaazi J; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Denti P; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Aber F; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Lamorde M; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Dooley KE; Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aarnoutse R; Radbound University, Radbound, Netherlands.
Sloan DJ; Division of Infection and Global Health, School of Medicine, University of St. Andrews, St. Andrews, Scotland.
Sekaggya-Wiltshire C; Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda. .
Pokaż więcej
Źródło :
Trials [Trials] 2020 Feb 13; Vol. 21 (1), pp. 181. Date of Electronic Publication: 2020 Feb 13.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Antibiotics, Antitubercular/*administration & dosage
Antitubercular Agents/*administration & dosage
Coinfection/*drug therapy
HIV Infections/*drug therapy
Rifampin/*administration & dosage
Tuberculosis/*drug therapy
Adult ; Alkynes/administration & dosage ; Alkynes/pharmacokinetics ; Antibiotics, Antitubercular/adverse effects ; Antibiotics, Antitubercular/pharmacokinetics ; Antitubercular Agents/adverse effects ; Antitubercular Agents/pharmacokinetics ; Benzoxazines/administration & dosage ; Benzoxazines/pharmacokinetics ; Clinical Trials, Phase II as Topic ; Coinfection/blood ; Cyclopropanes/administration & dosage ; Cyclopropanes/pharmacokinetics ; Cytochrome P-450 CYP2B6/metabolism ; Cytochrome P-450 CYP2B6 Inducers/administration & dosage ; Cytochrome P-450 CYP2B6 Inducers/adverse effects ; Cytochrome P-450 CYP2B6 Inducers/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Interactions ; Drug Monitoring ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; HIV Infections/blood ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Humans ; Male ; Middle Aged ; Oxazines/administration & dosage ; Oxazines/pharmacokinetics ; Piperazines/administration & dosage ; Piperazines/pharmacokinetics ; Pyridones/administration & dosage ; Pyridones/pharmacokinetics ; Randomized Controlled Trials as Topic ; Rifampin/adverse effects ; Rifampin/pharmacokinetics ; Treatment Outcome ; Tuberculosis/blood ; Uganda
Czasopismo naukowe
Tytuł :
Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
Autorzy :
Katende B; Division of Epidemiology and Biostatistics, Stellenbosch University, Tygerberg, South Africa. .; Elizabeth Glaser Pediatric Aids Foundation, Maseru, Lesotho. .
Esterhuizen TM; Division of Epidemiology and Biostatistics, Stellenbosch University, Tygerberg, South Africa.
Dippenaar A; DST-NRF Centre for Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Warren RM; DST-NRF Centre for Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Feb 05; Vol. 10 (1), pp. 1917. Date of Electronic Publication: 2020 Feb 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibiotics, Antitubercular/*pharmacology
Mycobacterium tuberculosis/*isolation & purification
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*diagnosis
Tuberculosis, Pulmonary/*diagnosis
Adolescent ; Adult ; Antibiotics, Antitubercular/standards ; Antibiotics, Antitubercular/therapeutic use ; Drug Resistance, Bacterial ; Female ; Fluoroquinolones/pharmacology ; Fluoroquinolones/therapeutic use ; Follow-Up Studies ; Humans ; Lesotho/epidemiology ; Male ; Microbial Sensitivity Tests/standards ; Microbial Sensitivity Tests/statistics & numerical data ; Middle Aged ; Mycobacterium tuberculosis/drug effects ; Practice Guidelines as Topic ; Retrospective Studies ; Rifampin/therapeutic use ; Sputum/microbiology ; Time-to-Treatment/standards ; Time-to-Treatment/statistics & numerical data ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/microbiology ; Tuberculosis, Multidrug-Resistant/mortality ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/microbiology ; Tuberculosis, Pulmonary/mortality ; Young Adult
Czasopismo naukowe
Tytuł :
Corneal Deposits in a Patient With Anti-Interferon-γ Autoantibody Syndrome.
Autorzy :
Ahmad TR; School of Medicine, University of California, San Francisco.
Ashraf DC; Department of Ophthalmology, University of California, San Francisco.
Seitzman GD; Department of Ophthalmology, University of California, San Francisco.; Francis I. Proctor Foundation, University of California, San Francisco.
Pokaż więcej
Źródło :
JAMA ophthalmology [JAMA Ophthalmol] 2020 Mar 01; Vol. 138 (3), pp. 310-311.
Typ publikacji :
Case Reports
MeSH Terms :
Antibiotics, Antitubercular/*adverse effects
Autoantibodies/*analysis
Autoimmune Diseases/*drug therapy
Cornea/*drug effects
Corneal Opacity/*chemically induced
Immunologic Factors/*administration & dosage
Interferon-gamma/*immunology
Mycobacterium avium-intracellulare Infection/*drug therapy
Rifabutin/*adverse effects
Rituximab/*administration & dosage
Adult ; Antibiotics, Antitubercular/analysis ; Autoimmune Diseases/diagnosis ; Autoimmune Diseases/immunology ; Cornea/chemistry ; Cornea/pathology ; Corneal Opacity/diagnosis ; Corneal Opacity/metabolism ; Female ; Humans ; Immunocompromised Host ; Immunologic Factors/adverse effects ; Mycobacterium avium-intracellulare Infection/diagnosis ; Mycobacterium avium-intracellulare Infection/microbiology ; Rifabutin/analysis ; Risk Factors ; Rituximab/adverse effects ; Syndrome
Raport
Tytuł :
Accuracy of Xpert MTB/RIF Ultra for the Diagnosis of Pleural TB in a Multicenter Cohort Study.
Autorzy :
Wang G; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Wang S; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Yang X; Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Sun Q; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Jiang G; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Huang M; Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Huo F; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Ma Y; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Chen X; Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China. Electronic address: .
Huang H; National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China.
Pokaż więcej
Źródło :
Chest [Chest] 2020 Feb; Vol. 157 (2), pp. 268-275. Date of Electronic Publication: 2019 Aug 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibiotics, Antitubercular*
Rifampin*
Drug Resistance, Microbial/*genetics
Mycobacterium tuberculosis/*genetics
Tuberculosis, Multidrug-Resistant/*diagnosis
Tuberculosis, Pleural/*diagnosis
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Culture Techniques ; Female ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Nucleic Acid Amplification Techniques ; Pleural Effusion ; Polymerase Chain Reaction ; Predictive Value of Tests ; Sensitivity and Specificity ; Young Adult
Czasopismo naukowe
Tytuł :
The impact of chest radiography and Xpert MTB/RIF testing among household contacts in Chennai, India.
Autorzy :
Ananthakrishnan R; REACH - Resource Group for Education and Advocacy for Community Health, Chennai, Tamil Nadu, India.
Thiagesan R; REACH - Resource Group for Education and Advocacy for Community Health, Chennai, Tamil Nadu, India.
Auguesteen S; REACH - Resource Group for Education and Advocacy for Community Health, Chennai, Tamil Nadu, India.
Karunakaran N; REACH - Resource Group for Education and Advocacy for Community Health, Chennai, Tamil Nadu, India.
Jayabal L; GCC RNTCP - Greater Chennai Corporation Revised National Tuberculosis Control Programme Chennai, Tamil Nadu, India.
M J; GCC RNTCP - Greater Chennai Corporation Revised National Tuberculosis Control Programme Chennai, Tamil Nadu, India.
Stevens R; Independent Consultant, Manchester, United Kingdom.
Codlin A; Stop TB Partnership, TB REACH, Geneva, Switzerland.
Creswell J; Stop TB Partnership, TB REACH, Geneva, Switzerland.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Nov 04; Vol. 15 (11), pp. e0241203. Date of Electronic Publication: 2020 Nov 04 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Contact Tracing/*methods
Mass Screening/*methods
Mycobacterium tuberculosis/*isolation & purification
Sputum/*microbiology
Tuberculosis, Pulmonary/*diagnosis
Adolescent ; Adult ; Antibiotics, Antitubercular/pharmacology ; Antibiotics, Antitubercular/therapeutic use ; Contact Tracing/statistics & numerical data ; Drug Resistance, Bacterial ; Female ; Humans ; India/epidemiology ; Male ; Mass Screening/statistics & numerical data ; Microscopy ; Middle Aged ; Molecular Diagnostic Techniques/statistics & numerical data ; Radiography/statistics & numerical data ; Reagent Kits, Diagnostic/statistics & numerical data ; Retrospective Studies ; Rifampin ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/epidemiology ; Tuberculosis, Pulmonary/microbiology ; Young Adult
Czasopismo naukowe
Tytuł :
High prevalence of rifampin-resistant tuberculosis in mountainous districts of India.
Autorzy :
Dorjee K; Center for TB Research, School of Medicine Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India. Electronic address: .
Sadutshang TD; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India.
Rana RS; Revised National TB Control Program, District TB Office, Kangra, India.
Topgyal S; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India.
Phunkyi D; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India.
Choetso T; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India.
Chodon T; Division of Tuberculosis, Tibetan Delek Hospital, Dharamsala, India.
Parmar M; World Health Organization, Central TB Division, Government of India, New Delhi, India.
Singla R; National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India.
Paster Z; Department of Family Medicine, University of Wisconsin, Wisconsin, USA.
Chaisson RE; Center for TB Research, School of Medicine Division of Infectious Diseases, Johns Hopkins University, Baltimore, USA.
Kaushal KC; World Health Organization, Revised National TB Control Program, State TB Office, Shimla, India.
Pokaż więcej
Źródło :
The Indian journal of tuberculosis [Indian J Tuberc] 2020 Jan; Vol. 67 (1), pp. 59-64. Date of Electronic Publication: 2019 Aug 17.
Typ publikacji :
Journal Article
MeSH Terms :
Antibiotics, Antitubercular*
Rifampin*
Tuberculosis, Multidrug-Resistant/*epidemiology
Adult ; Drug Resistance, Bacterial/genetics ; Female ; Health Services Accessibility ; Humans ; India ; Male ; Middle Aged ; Mycobacterium tuberculosis/genetics ; Nucleic Acid Amplification Techniques ; Patient Acceptance of Health Care ; Prevalence ; Private Sector ; Risk Factors ; Tuberculosis, Multidrug-Resistant/diagnosis ; Tuberculosis, Multidrug-Resistant/microbiology ; Tuberculosis, Multidrug-Resistant/transmission
Czasopismo naukowe
Tytuł :
Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
Autorzy :
Wasihun AG; Department of Medical Microbiology and Immunology, School of Medicine, Mekelle University, Mekelle, Ethiopia.
Dejene TA; Department of Medical Microbiology and Immunology, School of Medicine, Mekelle University, Mekelle, Ethiopia.; Department of Medical Microbiology and Immunology, School of Medicine, Aksum University, Aksum, Ethiopia.
Hailu GG; Department of Medical Microbiology and Immunology, School of Medicine, Mekelle University, Mekelle, Ethiopia.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Nov 04; Vol. 15 (11), pp. e0240361. Date of Electronic Publication: 2020 Nov 04 (Print Publication: 2020).
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Drug Resistance, Multiple, Bacterial/*drug effects
Mycobacterium tuberculosis/*drug effects
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antitubercular/pharmacology ; Biological Assay/methods ; Cross-Sectional Studies ; Ethiopia/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Mycobacterium tuberculosis/physiology ; Retrospective Studies ; Tuberculosis, Multidrug-Resistant/epidemiology ; Tuberculosis, Multidrug-Resistant/microbiology ; Young Adult
Czasopismo naukowe
Tytuł :
Genotyping of Mycobacterium tuberculosis Rifampin Resistance-Associated Mutations by Use of Data from Xpert MTB/RIF Ultra Enables Large-Scale Tuberculosis Molecular Epidemiology Studies.
Autorzy :
Weinrick B; Trudeau Institute, Saranac Lake, New York, USA .
Pokaż więcej
Źródło :
Journal of clinical microbiology [J Clin Microbiol] 2019 Dec 23; Vol. 58 (1). Date of Electronic Publication: 2019 Dec 23 (Print Publication: 2019).
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Antibiotics, Antitubercular*
Tuberculosis*
Mycobacterium tuberculosis/*genetics
Drug Resistance, Bacterial/drug effects ; Genotype ; Humans ; Molecular Epidemiology ; Mutation ; Rifampin ; Sensitivity and Specificity ; Temperature
Czasopismo naukowe
Tytuł :
Antimicrobial Lavandulylated Flavonoids from a Sponge-Derived Streptomyces sp. G248 in East Vietnam Sea.
Autorzy :
Cao DD; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.; Faculty of Chemistry, Graduate University of Science and Technology, VAST, Hanoi 11307, Vietnam.
Trinh TTV; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Mai HDT; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.; Faculty of Chemistry, Graduate University of Science and Technology, VAST, Hanoi 11307, Vietnam.
Vu VN; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Le HM; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Thi QV; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Nguyen MA; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Duong TT; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Tran DT; Institute of Applied Science and Technology, University Industry of Vinh, Vinh 43115, Vietnam.
Chau VM; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam.
Ma R; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
Shetye G; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
Cho S; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA.
Murphy BT; Department of Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60607, USA.
Pham VC; Advanced Center for Bioorganic Chemistry, Institute of Marine Biochemistry, Vietnam Academy of Science and Technology (VAST), Hanoi 11307, Vietnam. .
Pokaż więcej
Źródło :
Marine drugs [Mar Drugs] 2019 Sep 10; Vol. 17 (9). Date of Electronic Publication: 2019 Sep 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antibiotics, Antitubercular/*pharmacology
Flavonoids/*pharmacology
Porifera/*microbiology
Streptomyces/*chemistry
Animals ; Antibiotics, Antitubercular/chemistry ; Antibiotics, Antitubercular/isolation & purification ; Cell Line, Tumor ; Circular Dichroism ; Flavonoids/chemistry ; Flavonoids/isolation & purification ; Magnetic Resonance Spectroscopy ; Microbial Sensitivity Tests ; Molecular Structure ; Mycobacterium tuberculosis/drug effects ; Spectrometry, Mass, Electrospray Ionization ; Vietnam
Czasopismo naukowe
Tytuł :
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Autorzy :
Abulfathi AA; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa. .
Decloedt EH; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa.
Svensson EM; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
Diacon AH; Task Applied Science, Bellville, South Africa.; Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Donald P; Paediatrics and Child Health and Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Reuter H; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, PO Box 241, Cape Town, 8000, South Africa.
Pokaż więcej
Źródło :
Clinical pharmacokinetics [Clin Pharmacokinet] 2019 Sep; Vol. 58 (9), pp. 1103-1129.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antibiotics, Antitubercular/*pharmacology
Drug Monitoring/*methods
Microbial Sensitivity Tests/*methods
Rifampin/*pharmacology
Tuberculosis/*drug therapy
Administration, Oral ; Adult ; Antibiotics, Antitubercular/administration & dosage ; Antibiotics, Antitubercular/economics ; Antibiotics, Antitubercular/pharmacokinetics ; Biological Variation, Population/drug effects ; Comorbidity ; Drug Resistance ; Drug Therapy, Combination/methods ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Mortality ; Pharmacogenetics/methods ; Pyrazinamide/administration & dosage ; Pyrazinamide/pharmacology ; Pyrazinamide/therapeutic use ; Rifampin/administration & dosage ; Rifampin/economics ; Rifampin/pharmacokinetics
Czasopismo naukowe
Tytuł :
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Autorzy :
Rawizza HE; Brigham and Women's Hospital, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Darin KM; Northwestern University School of Professional Studies, Chicago, IL, USA.
Oladokun R; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
Brown B; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
Ogunbosi B; College of Medicine, University of Ibadan, University College Hospital, Ibadan, Nigeria.
David N; Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria.
Akanmu S; University of Lagos, Lagos State, Nigeria.
Olaitan O; APIN Public Health Initiatives, Abuja, Nigeria.
Chang C; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Scarsi KK; University of Nebraska Medical Center, Omaha, NE, USA.
Okonkwo P; APIN Public Health Initiatives, Abuja, Nigeria.
Kanki PJ; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 Sep 01; Vol. 74 (9), pp. 2707-2715.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Antibiotics, Antitubercular/*therapeutic use
Coinfection/*drug therapy
HIV Infections/*drug therapy
Lopinavir/*therapeutic use
Rifabutin/*therapeutic use
Ritonavir/*therapeutic use
Tuberculosis/*drug therapy
Antibiotics, Antitubercular/administration & dosage ; Antibiotics, Antitubercular/adverse effects ; Antiretroviral Therapy, Highly Active ; Biomarkers ; Drug Interactions ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/etiology ; Female ; HIV Infections/virology ; Humans ; Male ; Retrospective Studies ; Rifabutin/administration & dosage ; Rifabutin/adverse effects ; Treatment Outcome ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł :
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
Autorzy :
Wang X; Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK. Electronic address: .
Cerrone M; St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
Ferretti F; St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
Castrillo N; St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
Maartens G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
McClure M; Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK.
Boffito M; Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College London, London, UK; St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK.
Pokaż więcej
Źródło :
International journal of antimicrobial agents [Int J Antimicrob Agents] 2019 Aug; Vol. 54 (2), pp. 202-206. Date of Electronic Publication: 2019 Apr 16.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Interactions*
Antibiotics, Antitubercular/*administration & dosage
HIV Integrase Inhibitors/*administration & dosage
Heterocyclic Compounds, 3-Ring/*administration & dosage
Rifampin/*administration & dosage
Adolescent ; Adult ; Antibiotics, Antitubercular/pharmacokinetics ; Antibiotics, Antitubercular/pharmacology ; Female ; HIV Integrase Inhibitors/pharmacokinetics ; HIV Integrase Inhibitors/pharmacology ; Healthy Volunteers ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Heterocyclic Compounds, 3-Ring/pharmacology ; Humans ; Middle Aged ; Oxazines ; Piperazines ; Pyridones ; Rifampin/pharmacokinetics ; Rifampin/pharmacology ; Young Adult
Czasopismo naukowe
Tytuł :
Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis.
Autorzy :
Sekaggya-Wiltshire C; a Infectious Diseases Institute, Makerere University College of Health Sciences , Kampala , Uganda.
Dooley KE; b Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore , USA.
Pokaż więcej
Źródło :
Expert opinion on drug metabolism & toxicology [Expert Opin Drug Metab Toxicol] 2019 Aug; Vol. 15 (8), pp. 615-618. Date of Electronic Publication: 2019 Jul 30.
Typ publikacji :
Editorial
MeSH Terms :
Antibiotics, Antitubercular/*administration & dosage
Rifamycins/*administration & dosage
Tuberculosis/*drug therapy
Antibiotics, Antitubercular/pharmacokinetics ; Antibiotics, Antitubercular/pharmacology ; Dose-Response Relationship, Drug ; Drug Interactions ; Humans ; Rifamycins/pharmacokinetics ; Rifamycins/pharmacology
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies